SPECIAL NOTICE
B -- Evaluation of MaxForce TMS Doxycycline & Fipronil Bait Box Field Study for the Reduction of Lyme Disease
- Notice Date
- 5/13/2010
- Notice Type
- Special Notice
- NAICS
- 541620
— Environmental Consulting Services
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 00HCVHCC-2010-83278
- Archive Date
- 5/21/2010
- Point of Contact
- Linda M Young, Phone: (770) 488-2655
- E-Mail Address
-
lml3@cdc.gov
(lml3@cdc.gov)
- Small Business Set-Aside
- N/A
- Description
- The Centers for Disease Control and Prevention intends to issue a sole source purchase order to Terry L. Schulze, 9 Evergreen, Perrinville, CT 08535, for the Evaluation of MaxForce Doxycycline and Fipronil Bait Box Field Study for the Reduction of Lyme Disease. Lyme disease, caused by the spirochete Borrelia burgdorferi, and transmitted by the black-legged tick, Ixodes scapularis, is the most commonly reported vector-borne disease in the United States. Although chemical pesticides and repellents are available to combat these disease transmitting pests, many citizens are hesitant about the use of these pesticides due to concerns about short range toxicity and long range health problems attributed to these chemicals. DVBID scientists have developed host-targeted methods of controlling disease vectors thereby reducing populations of infected rodent reservoirs and questing ticks. Development of new, environmentally safe vector-control methods is a very high priority for DVBID and CDC. Because these DVIBD patented, host-targeted bait boxes and other host-targeted technologies use such small amounts of pesticides enclosed in a box, they provide an especially eco-friendly method of vector-borne disease control in a residential setting. This is a win-win solution both for public health and the environment. The latest development of host-targeted technologies comes as a new adaptation to the bait box technology. Initial studies were performed in DVBID laboratories. A novel doxycycline hyclate impregnated bait formulation was shown to be efficacious in preventing tick-transmitted B. burgdorferi infection as well as providing a cure for early established infection in a murine model of Lyme borreliosis. In addition, this doxycycline bait formulation, encompassing a bacteriostatic drug, demonstrated the unexpected result of clearing spirochete infection in feeding ticks. These data provide evidence for exploring alternative techniques to prevent transmission of Lyme disease spirochetes. These studies were performed at CDC, DVBID and have been published in the Amer J Trop Med and Hyg (Dolan et al. 2008. 78:803-805). The purpose of this project is as follows: To evaluate the ability of modified Maxforce Tick Management System (TMS) bait boxes that contain the acaricide fipronil and are retrofitted with Doxycycline hyclate proprietary rodent baits formulated at 500 mg/Kg. Bait boxes will be serviced weekly. The ability of this dual system bait box to prophylactically protect mice, cure infected mice, and clear ticks feeding on treated mice with the use of doxycycline bait and the ability of fipronil-treated wicks to kill ticks on rodent hosts and to significantly decrease overall populations of questing ticks that transmit the spirochete that causes Lyme disease, Borrelia burgdorferi, and the agent, Anaplasmosis phagocytophilum in Peromyscus leucopus, Tamias striatus, Sciurus carolinensis, and Blarina brevicauda, the primary reservoirs of these two vector-borne diseases will be determined. The Scope of Work is as follows: The vendor shall furnish all labor, materials and equipment necessary to evaluate the efficacy of doxycycline hyclate palatable rodent baits formulated at 500 mg/Kg. This will include but is not limited to all necessary equipment to perform rodent reservoir and questing tick evaluations. The vendor will need to have access to suitable tick/rodent/Lyme disease habitat with a minimum of 0.1 tick/m2 and adequate species of Peromyscus leucopus, Tamias striatus, Sciurus carolinensis, and Blarina brevicauda. The vendor shall furnish all labor, materials, processing equipment, live mammalian traps (Sherman and Tomahawk), bait boxes, and equipment necessary to evaluate the efficacy of doxycycline impregnated rodent bait to reduce infected rodent reservoirs and infected questing ticks and fipronil to decrease tick populations in residential areas. The vendor will identify suitable test plots for each study, conduct weekly pre- and post-treatment flagging and trapping of animals in plots to determine the ability of these host-targeted technologies to kill ticks, reduce infected reservoirs, and reduce the risk of tick-borne diseases. Vendor will provide weekly reports and perform statistical analysis. All data will be sent to CDC/NCID/DVBID, Fort Collins, CO. The DVBID contract PI will provide all additional equipment as needed to properly process and evaluate rodents and ticks for infection and assess serum plasma levels of doxycycline in target rodents (this includes but is not limited to: BSK, specimen vials, animal processing equipment, tick collection and processing equipment, HPLC and PCR analysis, culture and microscopy work, bait, bait boxes, data collection, generation, and evaluation). The DVBID contract PI will assist grantees with all field trials until completed. Tasks to be performed under this requirement: The vendor shall perform the following tasks in the order shown: (1) Locate, measure, and stake a total of 4-5, 5 hectare plots for evaluating doxycycline hyclate impregnated rodent bait formulated at 500 mg/Kg for controlling tick-borne disease in rodent reservoirs in Perrineville, NJ. There will be 2 untreated control plots and 2-3 treated plots. Treated plots will contain modified Masforce TMS bait boxes with both doxycycyline bait and fipronil-treated wicks. These plots will be sampled 2 times at weekly intervals to determine tick density, rodent density, rodent infestation rate, rodent infection rates, and tick infection rates prior to setting out bait boxes with the following objectives being performed: rodents will be trapped using Sherman and Tomahawk live traps. All rodent captures will be processed for materials to by analyzed for bait efficacy as follows: anesthetized, ear biopsied, bled by cheek punch, physical measurements recorded, ectoparisites removed and placed in ETOH, ear-tagged, and released at the capture site. Ear biopsies will be surface sterilized and cultured in BSK-H media for detection of live spirochetes by dark-field microscopy. Tick pools and blood samples collected from rodents will be screened for infection with B. burgdorferi and A. phagocytophium by PCR. Both sites will be flagged for questing nymphal ticks. Ticks will be individually screened by PCR for infection with Bb. (Secondary future analysis will include PCR for Ap). Both areas will be flagged for questing ticks. Collected ticks will be recorded and analyzed by PCR. (2) Bait box placement will take place at the conclusion of the pre-treatment work: Set out bait boxes on treated and untreated project sites. Treatment sites will receive 25 modified Maxforce TMS bait boxes each (100 bait boxes total over 4 properties) with both doxycycline bait and fipronil-treated wicks. The untreated control sites will have no bait boxes. (3) All sites will be evaluated at 4 and 14 wk post-bait box deployment. A single Tomahawk and Sherman traps will be set in immediate proximity to each bait station. This equates to 100 trap nights/site or 400 total/night. The areas will be trapped 2 consecutive nights (800 trap nights/sample period). All captures will be anesthetized, ear biopsied, bled by cheek-punch, physical measurements recorded, ectoparasites removed and placed in ETOH, ear-tagged, and released at the point of capture. Ear biopsies will be surface sterilized and cultured in BSK-H media and read by dark-field microscopy for detection of live spirochetes. Tick pools will be screened for infection by PCR. (Secondary future analysis will include PCR for Ap). Whole bloods will be centrifuged, serum removed and screened by HPLC for determination of detectable doxy levels in plasma. Both sites will be flagged for questing nymphal ticks. Ticks will be screened for infection by PCR. All efficacy data will be recorded for each time point and data will be analyzed, statistical analysis performed, and written report provided to CDC. All laboratory and field work should be performed under GLP guidelines for future FDA/EPA registration. Animal work will need to be performed under an approved IACUC protocol so the data can be submitted for publication in a peer-reviewed journal. The period of performance shall commence upon receipt of a purchase order and shall continue for a period of 180 days. Minimum vendor requirements are: must be fully familiar with the process of evaluating tick control technologies including host-targeted devices, antibiotic impregnated rodent baits, and acaricides in a field setting. This includes but is not limited to: applying of chemicals, safety measures, locating and identifying suitable tick habitat, marking plots, flagging for questing ticks, proper times and conditions to flag for ticks, knowledge of deer ticks, lone star ticks, and Lyme disease, knowledge of trapping rodents, processing rodents for infection, assaying ticks by PCR, evaluating baits and tick control using host-targeted devices such as bait boxes. The vendor must be able to conduct the study at weekly intervals and evaluate data using statistical analysis including the Henderson method for comparing efficacy of treated vs. control plots. CDC believes that this requirement is met by only one provider. This procurement will be processed under the authority of FAR 6.302-1 and 6.302-2. Only one responsible source and no other sources will satisfy agency requirements. No solicitation is being issued. Interested persons may identify their interest and capability to respond to this requirement. This procurement is not set-aside for small business. For contractual questions contact Linda M. Young.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/00HCVHCC-2010-83278/listing.html)
- Place of Performance
- Address: Perrineville, New Jersey, United States
- Record
- SN02149425-W 20100515/100513235731-270a17740c353d7a20cb7cdde087c5f5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |